EXORPHIA is pioneering next-generation therapeutics based on extracellular vesicles (EVs) to deliver innovative medicines that surpass the limits of existing treatments.
Through proprietary technologies, we have established high-activity EVs (Prime-EV), engineered EVs that can be flexibly loaded with antigens or drugs (Engineered EV), and an Advanced CMC platform that ensures reproducibility—all underpinned by a robust patent portfolio.
Our lead pipeline comprises three pillars:
(1) an IVF adjunct for infertility treatment (commercial launch in Japan planned for 2027–2028)
(2) an anti-inflammatory/anti-fibrotic therapy targeting ARDS, IPF, and atopic dermatitis (EXP01; aiming for a disease-modifying profile)
(3) an intranasal EV vaccine (EXP03; applicable from infectious-disease prevention to autoimmunity and oncology).
Through these programs, we will deliver safe, minimally invasive, and highly effective new treatments to clinical practice, and ultimately establish EVs as a versatile DDS platform to set a new standard for refractory diseases and preventive medicine.
Additional questions
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Researched disease area / マッチングご希望の疾患領域
Researched Modality / マッチングご希望のモダリティ
Researched Technologies / マッチングご希望の技術
Project cooperation
EXP01-AD: Weekly SC MSC-EV Lead with Topical Option for Atopic Dermatitis
2026 update: low-dose weekly SC lead plus daily topical option. Severe AD mouse PoC showed TEWL close to the normal-group range and reduced skin thickening. Seeking nonclinical-stage licensing.
Project cooperation
EXP01 is a disease-modifying MSC-EV asset for IPF & ARDS, offering dual anti-inflammatory & anti-fibrotic efficacy without SOC toxicity. Backed by strong in vivo PoC, robust IP, and FDA pre-IND clearance, EXP01 is available for out-licensing.
Project cooperation
EXP03-INF: Engineered EV Platform for Multivalent Infectious-Disease Vaccines
Multivalent antigen/protein EV vaccine platform with mouse PoC; seeking an exclusive development and licensing partner.
Project cooperation
EXP05: MSC-EV Therapy for POI/DOR and Gynecologic Tissue Repair
Non-hormonal, cell-free tissue-repair candidate with ovarian PoC; seeking early option-based partnering and licensing.
Partnership
EXORPHIA, Inc. | Pioneering Next-Generation EV Therapeutics & DDS Platform.
EXORPHIA is a Japanese biotech pioneering EV therapeutics. Powered by Prime-EV™ & Engineered EV platforms with advanced CMC, we advance pipelines in dermatology, ARDS/IPF, vaccines, CNS, and ART. We seek partners for licensing, co-dev & DDS deals.